WO2021174167A1 - Composés et procédés de modulation de l'épissage - Google Patents
Composés et procédés de modulation de l'épissage Download PDFInfo
- Publication number
- WO2021174167A1 WO2021174167A1 PCT/US2021/020157 US2021020157W WO2021174167A1 WO 2021174167 A1 WO2021174167 A1 WO 2021174167A1 US 2021020157 W US2021020157 W US 2021020157W WO 2021174167 A1 WO2021174167 A1 WO 2021174167A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- heterocyclyl
- heteroaryl
- alkyl
- aryl
- Prior art date
Links
- 0 C*=C(C1CCCCCCC1)*=C(*)C(C(*=CC*C(CC/C1=C\CCCCCC1)=*)=C(C)[C@](CC1)NC1*=C)=* Chemical compound C*=C(C1CCCCCCC1)*=C(*)C(C(*=CC*C(CC/C1=C\CCCCCC1)=*)=C(C)[C@](CC1)NC1*=C)=* 0.000 description 63
- SBXRKVRUZNQPDQ-PLNGDYQASA-N C/C(/N=C(/C)\N)=C(\C)/N=[IH] Chemical compound C/C(/N=C(/C)\N)=C(\C)/N=[IH] SBXRKVRUZNQPDQ-PLNGDYQASA-N 0.000 description 2
- NGCXHCGUQHIOLZ-UHFFFAOYSA-N C[n]1nccn1 Chemical compound C[n]1nccn1 NGCXHCGUQHIOLZ-UHFFFAOYSA-N 0.000 description 2
- JWAWEQBUZOGIBZ-UHFFFAOYSA-N C[n]1nncc1 Chemical compound C[n]1nncc1 JWAWEQBUZOGIBZ-UHFFFAOYSA-N 0.000 description 2
- VMINESKAEYIIGU-UHFFFAOYSA-N Bc1ccc(C)c(CC(OC)=O)c1 Chemical compound Bc1ccc(C)c(CC(OC)=O)c1 VMINESKAEYIIGU-UHFFFAOYSA-N 0.000 description 1
- QDSISLOXUCQRJQ-AERCQKQUSA-N C(C1)[C@H](C2)N[C@@H]1C[C@H]2Nc(cc1CCOc2c3)ccc1-c2ccc3-c1c[nH]nc1 Chemical compound C(C1)[C@H](C2)N[C@@H]1C[C@H]2Nc(cc1CCOc2c3)ccc1-c2ccc3-c1c[nH]nc1 QDSISLOXUCQRJQ-AERCQKQUSA-N 0.000 description 1
- JCTWRKDNKHCDSI-UHFFFAOYSA-N CC(C)(C)NC1CNCC1 Chemical compound CC(C)(C)NC1CNCC1 JCTWRKDNKHCDSI-UHFFFAOYSA-N 0.000 description 1
- NZJKEPNCNBWESN-ILWJIGKKSA-N CC(C)(C)OC(N([C@H](CC1)C2)[C@@H]1C[C@H]2N)=O Chemical compound CC(C)(C)OC(N([C@H](CC1)C2)[C@@H]1C[C@H]2N)=O NZJKEPNCNBWESN-ILWJIGKKSA-N 0.000 description 1
- OWDAKLXROPITPH-CTCIOQLBSA-N CC(C)(C)OC(N([C@H]1[C@H](C2)C1C1)[C@@H]1C[C@H]2N)=O Chemical compound CC(C)(C)OC(N([C@H]1[C@H](C2)C1C1)[C@@H]1C[C@H]2N)=O OWDAKLXROPITPH-CTCIOQLBSA-N 0.000 description 1
- FTVFPPFZRRKJIH-UHFFFAOYSA-N CC(C)(C1)NC(C)(C)CC1N Chemical compound CC(C)(C1)NC(C)(C)CC1N FTVFPPFZRRKJIH-UHFFFAOYSA-N 0.000 description 1
- QYTYIKBOHJBBKQ-UHFFFAOYSA-N CC(C)(C1)NC(C)(C)CC1N(C)c(cc1)nc2c1-c(ccc(-c1c[nH]nc1)c1)c1OCC2 Chemical compound CC(C)(C1)NC(C)(C)CC1N(C)c(cc1)nc2c1-c(ccc(-c1c[nH]nc1)c1)c1OCC2 QYTYIKBOHJBBKQ-UHFFFAOYSA-N 0.000 description 1
- MTXZWLCURQPTAG-UHFFFAOYSA-N CC(C)C1CC(CC2)=[N]=C2C1 Chemical compound CC(C)C1CC(CC2)=[N]=C2C1 MTXZWLCURQPTAG-UHFFFAOYSA-N 0.000 description 1
- NENNWKFTJNLRSQ-UHFFFAOYSA-N CC(CC1)(C2)NC1(C)CC2S=C Chemical compound CC(CC1)(C2)NC1(C)CC2S=C NENNWKFTJNLRSQ-UHFFFAOYSA-N 0.000 description 1
- VVBMMWYCAMYUSW-UHFFFAOYSA-N CCCNCCCO Chemical compound CCCNCCCO VVBMMWYCAMYUSW-UHFFFAOYSA-N 0.000 description 1
- APCPBNNLVCVDPL-UHFFFAOYSA-N COC(c1nc(Cl)ccc1Br)=O Chemical compound COC(c1nc(Cl)ccc1Br)=O APCPBNNLVCVDPL-UHFFFAOYSA-N 0.000 description 1
- VJWDDRPEDLXFLY-UHFFFAOYSA-N COc1c(B(O)O)ccc(Br)c1 Chemical compound COc1c(B(O)O)ccc(Br)c1 VJWDDRPEDLXFLY-UHFFFAOYSA-N 0.000 description 1
- LBGSWBJURUFGLR-UHFFFAOYSA-N C[n]1ncc(N)c1 Chemical compound C[n]1ncc(N)c1 LBGSWBJURUFGLR-UHFFFAOYSA-N 0.000 description 1
- UQFQONCQIQEYPJ-UHFFFAOYSA-N C[n]1nccc1 Chemical compound C[n]1nccc1 UQFQONCQIQEYPJ-UHFFFAOYSA-N 0.000 description 1
- RIKMMFOAQPJVMX-UHFFFAOYSA-N Cc1c[nH]nc1 Chemical compound Cc1c[nH]nc1 RIKMMFOAQPJVMX-UHFFFAOYSA-N 0.000 description 1
- BLHTXORQJNCSII-UHFFFAOYSA-N Cc1c[n](C)cn1 Chemical compound Cc1c[n](C)cn1 BLHTXORQJNCSII-UHFFFAOYSA-N 0.000 description 1
- HGRXBKDKSYDWLD-UHFFFAOYSA-N Cc1cc(OC)ncc1 Chemical compound Cc1cc(OC)ncc1 HGRXBKDKSYDWLD-UHFFFAOYSA-N 0.000 description 1
- CGQFCGNAJCENNJ-UHFFFAOYSA-N Clc(cc1)nc2c1-c(ccc(-c1c[nH]nc1)c1)c1OCC2 Chemical compound Clc(cc1)nc2c1-c(ccc(-c1c[nH]nc1)c1)c1OCC2 CGQFCGNAJCENNJ-UHFFFAOYSA-N 0.000 description 1
- OTWJYQIPXZQDSQ-UHFFFAOYSA-N Clc1ccc2-c(ccc(-[n]3nccc3)c3)c3OCCc2n1 Chemical compound Clc1ccc2-c(ccc(-[n]3nccc3)c3)c3OCCc2n1 OTWJYQIPXZQDSQ-UHFFFAOYSA-N 0.000 description 1
- BNWOMTMQPXXXAE-UHFFFAOYSA-N Fc(cc1)nc(OCc2c3)c1-c2ccc3Br Chemical compound Fc(cc1)nc(OCc2c3)c1-c2ccc3Br BNWOMTMQPXXXAE-UHFFFAOYSA-N 0.000 description 1
- DRLSNKJIJAZROL-UHFFFAOYSA-N Nc(c(CCOc1cc(I)ccc1)c1)ccc1Br Chemical compound Nc(c(CCOc1cc(I)ccc1)c1)ccc1Br DRLSNKJIJAZROL-UHFFFAOYSA-N 0.000 description 1
- CWXILOUSRLPVCK-UHFFFAOYSA-N O=C1Oc(cc(cc2)-[n]3nccc3)c2-c(cc2)c1cc2Br Chemical compound O=C1Oc(cc(cc2)-[n]3nccc3)c2-c(cc2)c1cc2Br CWXILOUSRLPVCK-UHFFFAOYSA-N 0.000 description 1
- XZWKSFILNPLDDT-UHFFFAOYSA-N OCCc(nc(cc1)Cl)c1-c(ccc(-[n]1nccc1)c1)c1O Chemical compound OCCc(nc(cc1)Cl)c1-c(ccc(-[n]1nccc1)c1)c1O XZWKSFILNPLDDT-UHFFFAOYSA-N 0.000 description 1
- HCXPUOYZZQOSLS-UHFFFAOYSA-N OCCc(nc(cc1)Cl)c1-c(ccc(-c1c[nH]nc1)c1)c1O Chemical compound OCCc(nc(cc1)Cl)c1-c(ccc(-c1c[nH]nc1)c1)c1O HCXPUOYZZQOSLS-UHFFFAOYSA-N 0.000 description 1
- ANIBKTOFNMQNHK-UHFFFAOYSA-N OCc1cc(Br)ccc1-c(c(O)c1)ccc1-[n]1nccc1 Chemical compound OCc1cc(Br)ccc1-c(c(O)c1)ccc1-[n]1nccc1 ANIBKTOFNMQNHK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Priority Applications (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/802,827 US20230148184A1 (en) | 2020-02-28 | 2021-02-28 | Compounds and methods for modulating splicing |
IL295955A IL295955A (en) | 2020-02-28 | 2021-02-28 | Compounds and Methods for Splicing Regulation |
EP21713825.4A EP4110460A1 (fr) | 2020-02-28 | 2021-02-28 | Composés et procédés de modulation de l'épissage |
JP2022552207A JP2023515619A (ja) | 2020-02-28 | 2021-02-28 | スプライシングを調節するための化合物及び方法 |
AU2021228285A AU2021228285A1 (en) | 2020-02-28 | 2021-02-28 | Compounds and methods for modulating splicing |
CN202180030828.XA CN115485023A (zh) | 2020-02-28 | 2021-02-28 | 用于调节剪接的化合物和方法 |
MX2022010681A MX2022010681A (es) | 2020-02-28 | 2021-02-28 | Compuestos y metodos para modular el empalme. |
CA3169676A CA3169676A1 (fr) | 2020-02-28 | 2021-02-28 | Composes et procedes de modulation de l'epissage |
KR1020227033657A KR20220158237A (ko) | 2020-02-28 | 2021-02-28 | 스플라이싱을 조절하기 위한 화합물 및 방법 |
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202062983539P | 2020-02-28 | 2020-02-28 | |
US62/983,539 | 2020-02-28 | ||
US202063007145P | 2020-04-08 | 2020-04-08 | |
US63/007,145 | 2020-04-08 | ||
US202063040477P | 2020-06-17 | 2020-06-17 | |
US63/040,477 | 2020-06-17 | ||
US202063072919P | 2020-08-31 | 2020-08-31 | |
US63/072,919 | 2020-08-31 | ||
US202063126324P | 2020-12-16 | 2020-12-16 | |
US63/126,324 | 2020-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021174167A1 true WO2021174167A1 (fr) | 2021-09-02 |
Family
ID=75143750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2021/020157 WO2021174167A1 (fr) | 2020-02-28 | 2021-02-28 | Composés et procédés de modulation de l'épissage |
Country Status (10)
Country | Link |
---|---|
US (1) | US20230148184A1 (fr) |
EP (1) | EP4110460A1 (fr) |
JP (1) | JP2023515619A (fr) |
KR (1) | KR20220158237A (fr) |
CN (1) | CN115485023A (fr) |
AU (1) | AU2021228285A1 (fr) |
CA (1) | CA3169676A1 (fr) |
IL (1) | IL295955A (fr) |
MX (1) | MX2022010681A (fr) |
WO (1) | WO2021174167A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022026806A1 (fr) * | 2020-07-30 | 2022-02-03 | University Of Connecticut | Méthodes et compositions pour le traitement d'infections virales |
US11326165B1 (en) | 2017-08-04 | 2022-05-10 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
WO2023034833A1 (fr) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Composés et procédés de modulation de l'épissage |
US11806346B2 (en) | 2020-05-13 | 2023-11-07 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014028459A1 (fr) | 2012-08-13 | 2014-02-20 | Novartis Ag | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn |
US20150005289A1 (en) | 2012-02-10 | 2015-01-01 | Ptc Therapeutics Inc. | Compounds for treating spinal muscular atrophy |
US20160152628A1 (en) * | 2013-07-02 | 2016-06-02 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2016128343A1 (fr) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Composés pour le traitement d'un cancer |
WO2016196386A1 (fr) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Procédés de modulation de l'épissage de l'arn |
WO2017100726A1 (fr) | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Méthodes de traitement de la maladie de huntington |
WO2018098446A1 (fr) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Procédés de modulation de l'épissage de l'arn |
WO2018232039A1 (fr) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Procédés de modification de l'épissage de l'arn |
WO2019028440A1 (fr) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | Méthodes et compositions permettant de moduler l'épissageé |
WO2019060917A2 (fr) | 2017-09-25 | 2019-03-28 | Skyhawk Therapeutics, Inc. | Procédés et compositions de criblage et d'identification de modulateurs d'épissage |
WO2019199972A1 (fr) | 2018-04-10 | 2019-10-17 | Skyhawk Therapeutics, Inc. | Composés pour le traitement d'un cancer |
-
2021
- 2021-02-28 IL IL295955A patent/IL295955A/en unknown
- 2021-02-28 EP EP21713825.4A patent/EP4110460A1/fr active Pending
- 2021-02-28 KR KR1020227033657A patent/KR20220158237A/ko unknown
- 2021-02-28 AU AU2021228285A patent/AU2021228285A1/en active Pending
- 2021-02-28 MX MX2022010681A patent/MX2022010681A/es unknown
- 2021-02-28 JP JP2022552207A patent/JP2023515619A/ja active Pending
- 2021-02-28 WO PCT/US2021/020157 patent/WO2021174167A1/fr unknown
- 2021-02-28 US US17/802,827 patent/US20230148184A1/en active Pending
- 2021-02-28 CN CN202180030828.XA patent/CN115485023A/zh active Pending
- 2021-02-28 CA CA3169676A patent/CA3169676A1/fr active Pending
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150005289A1 (en) | 2012-02-10 | 2015-01-01 | Ptc Therapeutics Inc. | Compounds for treating spinal muscular atrophy |
WO2014028459A1 (fr) | 2012-08-13 | 2014-02-20 | Novartis Ag | Analogues de pyridazine 1,4-disubstituée et procédés de traitement de troubles liés à une déficience en smn |
US8729263B2 (en) | 2012-08-13 | 2014-05-20 | Novartis Ag | 1,4-disubstituted pyridazine analogs there of and methods for treating SMN-deficiency-related conditions |
US20160152628A1 (en) * | 2013-07-02 | 2016-06-02 | Bristol-Myers Squibb Company | Tricyclic pyrido-carboxamide derivatives as rock inhibitors |
WO2016128343A1 (fr) | 2015-02-09 | 2016-08-18 | F. Hoffmann-La Roche Ag | Composés pour le traitement d'un cancer |
WO2016196386A1 (fr) | 2015-05-30 | 2016-12-08 | Ptc Therapeutics, Inc. | Procédés de modulation de l'épissage de l'arn |
WO2017100726A1 (fr) | 2015-12-10 | 2017-06-15 | Ptc Therapeutics, Inc. | Méthodes de traitement de la maladie de huntington |
WO2018098446A1 (fr) | 2016-11-28 | 2018-05-31 | Ptc Therapeutics, Inc | Procédés de modulation de l'épissage de l'arn |
WO2018232039A1 (fr) | 2017-06-14 | 2018-12-20 | Ptc Therapeutics, Inc. | Procédés de modification de l'épissage de l'arn |
WO2019028440A1 (fr) | 2017-08-04 | 2019-02-07 | Skyhawk Therapeutics, Inc. | Méthodes et compositions permettant de moduler l'épissageé |
WO2019060917A2 (fr) | 2017-09-25 | 2019-03-28 | Skyhawk Therapeutics, Inc. | Procédés et compositions de criblage et d'identification de modulateurs d'épissage |
WO2019199972A1 (fr) | 2018-04-10 | 2019-10-17 | Skyhawk Therapeutics, Inc. | Composés pour le traitement d'un cancer |
Non-Patent Citations (13)
Title |
---|
"Handbook of Chemistry and Physics", CAS, article "Periodic Table of the Elements" |
BERGE ET AL., JOURNAL OF PHARMACEUTICAL SCIENCE, vol. 66, 1977, pages 1 - 19 |
CARRUTHERS: "Some Modern Methods of Organic Synthesis", 1987, CAMBRIDGE UNIVERSITY PRESS |
ELIEL: "Stereochemistry of Carbon Compounds", 1962, MCGRAW-HILL |
FAUSTINOCOOPER, GENES DEV, vol. 17, no. 4, 2003, pages 419 - 37 |
GREENE ET AL.: "Protecting Groups in Organic Synthesis", 1991, WILEY |
JACQUES ET AL.: "Enantiomers, Racemates and Resolutions", 1981, WILEY INTERSCIENCE |
LAROCK: "Comprehensive Organic Transformations", 1989, VCH PUBLISHERS, INC. |
SMITHMARCH: "March's Advanced Organic Chemistry", 2001, JOHN WILEY & SONS, INC. |
THOMAS SORRELL: "Organic Chemistry", 1999, UNIVERSITY SCIENCE BOOKS |
WALKER: "Cambridge Dictionary of Biology", 1990, CAMBRIDGE UNIVERSITY PRESS |
WILEN ET AL., TETRAHEDRON, vol. 33, 1977, pages 2725 |
WILEN: "Tables of Resolving Agents and Optical Resolutions", 1972, UNIV. OF NOTRE DAME PRESS, pages: 268 |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11326165B1 (en) | 2017-08-04 | 2022-05-10 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
US11434489B1 (en) | 2017-08-04 | 2022-09-06 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
US11603531B1 (en) | 2017-08-04 | 2023-03-14 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
US11806346B2 (en) | 2020-05-13 | 2023-11-07 | Chdi Foundation, Inc. | HTT modulators for treating Huntington's disease |
WO2022026806A1 (fr) * | 2020-07-30 | 2022-02-03 | University Of Connecticut | Méthodes et compositions pour le traitement d'infections virales |
WO2023034833A1 (fr) * | 2021-08-30 | 2023-03-09 | Remix Therapeutics Inc. | Composés et procédés de modulation de l'épissage |
Also Published As
Publication number | Publication date |
---|---|
IL295955A (en) | 2022-10-01 |
AU2021228285A1 (en) | 2022-09-29 |
CA3169676A1 (fr) | 2021-09-02 |
MX2022010681A (es) | 2023-03-21 |
EP4110460A1 (fr) | 2023-01-04 |
US20230148184A1 (en) | 2023-05-11 |
KR20220158237A (ko) | 2022-11-30 |
CN115485023A (zh) | 2022-12-16 |
JP2023515619A (ja) | 2023-04-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021228286A1 (en) | Pyridazine derivatives for modulating nucleic acid splicing | |
EP4110785A1 (fr) | Composés bicycliques fusionnés utiles pour moduler l'épissage d'acide nucléique | |
EP4110460A1 (fr) | Composés et procédés de modulation de l'épissage | |
WO2021207532A1 (fr) | Composés et procédés de modulation de l'épissage | |
AU2021253571A1 (en) | Compounds and methods for modulating splicing | |
EP4110775A1 (fr) | Dérivés de thiophényle utiles pour moduler l'épissage d'acide nucléique | |
IL299543A (en) | 2-(Indazol-5-yl)-6-(piperidin-4-yl)-1,7-naphthyridine derivatives and related compounds as nucleic acid splicing modulators and for the treatment of multiple diseases | |
WO2023034833A1 (fr) | Composés et procédés de modulation de l'épissage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21713825 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2022552207 Country of ref document: JP Kind code of ref document: A Ref document number: 3169676 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2021228285 Country of ref document: AU Date of ref document: 20210228 Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2021713825 Country of ref document: EP Effective date: 20220928 |